PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026Polymers for Advanced Technologies1 citations

Engineered Copper Sulfide Nanoparticles Functionalized With Poly (N‐Vinylcaprolactam) for Sustained and Controlled Teriflunomide Release in Multiple Sclerosis Treatment: RSM Optimization and In Vitro Evaluation

View Full Paper
NSNazanin SayahiMMMohammadreza MahdavijalalHPHomayon Ahmad Panahi

Key Points

  • The aim is to develop a thermo-responsive nanocarrier for targeted and sustained delivery of teriflunomide in multiple sclerosis treatment.
  • Characterization using scanning electron microscopy and Fourier-transform infrared analysis.
  • Optimization via response surface methodology and central composite design.
  • Evaluation of TFM release in simulated body fluids at varying temperatures.
  • 94.06% TFM release observed at 45°C over 6 hours, compared to 60.6% at 37°C.
  • Kinetic data followed the zero-order model.
  • Korsmeyer-Peppas model indicated a supercase II transport mechanism.

Abstract

ABSTRACT In recent decades, significant efforts have been performed to develop drug delivery techniques for the treatment of Multiple Sclerosis (MS). This paper introduces a thermo‐responsive nanocarrier for targeted delivery of Teriflunomide (TFM) in MS patients, utilizing modified CuS nanoparticles (NPs) with poly(N‐vinylcaprolactam) and allyl alcohol. Characterization of the synthesized nanocarrier was conducted using scanning electron microscopy, Fourier‐transform infrared, x‐ray diffraction, and thermogravimetric analysis. Response surface methodology and central composite design models were employed to optimize three effective parameters: solution pH (6.49), temperature (25°C), and contact time (9.46 min). The isotherm adsorption and kinetic data showed the best fit with Langmuir ( q max = 6.0532 mg g −1 ) and pseudo‐second‐order models. The in vitro experiment for TFM release was monitored in simulated body fluids (pH = 7.4) at temperatures of 37°C and 45°C. The results revealed that 94.06% of TFM is released at 45°C during 6 h, compared to 60.6% at 37°C. Kinetic data analysis followed the zero‐order model, and the Korsmeyer‐Peppas model confirmed a supercase II transport mechanism for TFM release. Overall, the proposed nanocarrier showed promising potential for controlled, targeted delivery of TFM in MS patients.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sayahi et al. (2026) studied this question.

synapsesocial.com/papers/698828330fc35cd7a8847831https://doi.org/10.1002/pat.70487
Ask AI
Helpful
Bookmark
Share
View Full Paper